Low-density lipoprotein cholesterol and risk of COPD: a Mendelian randomization study

Statins have shown effects on exacerbation rates and lung function in individuals with chronic obstructive pulmonary disease (COPD) in randomized controlled trials. This has led to speculation that elevated LDL cholesterol may increase the risk of adverse COPD outcomes. We tested the hypothesis that high LDL cholesterol is causally associated with increased risk of severe COPD exacerbation, COPD-specific mortality, and spirometric COPD through a one-sample Mendelian randomization study design using individual-level data in two cohorts. We examined 108,438 adults from the Copenhagen General Population Study (CGPS). A weighted allele score was calculated using nine biologically relevant genetic variants associated with LDL cholesterol levels, and causal risk estimates for the three outcomes were determined using instrumental variable analysis. Findings were validated using one-sample Mendelian randomization in 389,627 individuals from the UK Biobank (UKB). Causal odds ratios from the CGPS were not statistically significant for severe COPD exacerbation (odds ratio (OR) 1.12 (95% CI: 0.88–1.42), p = 0.34) or COPD-specific mortality (OR 1.08 (0.69–1.69), p = 0.74). Similar findings were seen in the UKB. Causal estimates showed a decreased risk of cross-sectional spirometric COPD with 1 mmol/L (39 mg/dL) higher LDL cholesterol in the CGPS (OR 0.78 (0.66–0.92), p < 0.001); however, causal estimates were not statistically significant in the UKB (OR 1.03 (0.95–1.11), p = 0.50). Sensitivity analyses using MR Egger, inverse-variance weighted, weighted median, and weighted mode methods did not indicate a true causal association for any outcome in either cohort. In conclusion, in the CGPS and UKB, high LDL cholesterol did not causally increase the risk of severe COPD exacerbation and COPD-specific mortality. Further, our findings do not provide consistent evidence to support a causal role of high LDL cholesterol in reducing the risk of developing COPD.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-04-15
DOI
https://doi.org/10.1038/s41598-026-48823-6
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Low-density lipoprotein cholesterol and risk of COPD: a Mendelian randomization study

Sarah C. W. Marott, Benjamin Nilsson Wadström, Eskild Landt, B G Nordestgaard et al.
Scientific Reports
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Low-density lipoprotein cholesterol and risk of COPD: a Mendelian randomization study

Sarah C. W. Marott, Benjamin Nilsson Wadström, Eskild Landt, B G Nordestgaard, Josefine Freyberg Justesen, Shoaib Afzal, Morten Dahl
article en

Abstract

Statins have shown effects on exacerbation rates and lung function in individuals with chronic obstructive pulmonary disease (COPD) in randomized controlled trials. This has led to speculation that elevated LDL cholesterol may increase the risk of adverse COPD outcomes. We tested the hypothesis that high LDL cholesterol is causally associated with increased risk of severe COPD exacerbation, COPD-specific mortality, and spirometric COPD through a one-sample Mendelian randomization study design using individual-level data in two cohorts. We examined 108,438 adults from the Copenhagen General Population Study (CGPS). A weighted allele score was calculated using nine biologically relevant genetic variants associated with LDL cholesterol levels, and causal risk estimates for the three outcomes were determined using instrumental variable analysis. Findings were validated using one-sample Mendelian randomization in 389,627 individuals from the UK Biobank (UKB). Causal odds ratios from the CGPS were not statistically significant for severe COPD exacerbation (odds ratio (OR) 1.12 (95% CI: 0.88–1.42), p = 0.34) or COPD-specific mortality (OR 1.08 (0.69–1.69), p = 0.74). Similar findings were seen in the UKB. Causal estimates showed a decreased risk of cross-sectional spirometric COPD with 1 mmol/L (39 mg/dL) higher LDL cholesterol in the CGPS (OR 0.78 (0.66–0.92), p < 0.001); however, causal estimates were not statistically significant in the UKB (OR 1.03 (0.95–1.11), p = 0.50). Sensitivity analyses using MR Egger, inverse-variance weighted, weighted median, and weighted mode methods did not indicate a true causal association for any outcome in either cohort. In conclusion, in the CGPS and UKB, high LDL cholesterol did not causally increase the risk of severe COPD exacerbation and COPD-specific mortality. Further, our findings do not provide consistent evidence to support a causal role of high LDL cholesterol in reducing the risk of developing COPD.

Scientific Reports
University of Copenhagen (DK), Herlev Hospital (DK), Gentofte Hospital (DK), Danish Ministry of Defence (DK), Zealand University Hospital (DK)
Good health and well-being
Openalex Percentile: Top 7%
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.